66. IgA腎症 ［臨床試験数：125，薬物数：151（DrugBank：51），標的遺伝子数：30，標的パスウェイ数：111］
Searched query = "IgA nephropathy", "IgA nephritis", "Berger disease", "IgA IgG nephropathy"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1900026883 | 2019-12-01 | 28 October 2019 | A prospective randomized controlled trial of a new method for glucocorticoid intervention in progressive IgA nephropathy | A prospective randomized controlled trial of a new method for glucocorticoid intervention in progressive IgA nephropathy | IgA nephropathy | 1: 0.5mg/kg.d prednisolone induced remission;2:0.8mg/kg.d prednisolone induced remission ; | Nephrology Department, Hangzhou Hospital of Traditional Chinese Medicine, Zhejiang Province | Not Recruiting | 18 | 72 | Both | 1:71;2:71; | Phase 0 | China | |
| 2 | NCT04014335 | November 2019 | 11 November 2019 | A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy | An Open-Label Phase 2a Clinical Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Subjects With Primary IgA Nephropathy | Primary IgA Nephropathy | Drug: IONIS-FB-LRx | Ionis Pharmaceuticals, Inc. | Recruiting | 18 Years | 75 Years | All | 10 | Phase 2 | Australia;Canada;New Zealand | |
| 3 | NCT04020328 | August 1, 2019 | 29 July 2019 | Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency | A Randomized, Controlled Trial to Evaluate Leflunomide Plus Low Dose Corticosteroid Therapy in Progressive IgA Nephropathy With Renal Insufficiency | Glomerulonephritis, IGA;Renal Insufficiency, Chronic | Drug: Leflunomide 20 mg+prednisone 0.5mg/kg/d | Shenzhen Second People's Hospital | Not recruiting | 14 Years | 65 Years | All | 70 | Phase 4 | ||
| 4 | NCT03418779 | July 1, 2019 | 26 August 2019 | Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in Patients of IgA Nephropathy With High-risk of ESRD | Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in Patients of IgA Nephropathy With High-risk of ESRD | IgA Nephropathy at High Risk of Developing ESRD | Drug: The Yi-Qi-Qing-Jie Herbal Compound;Drug: Immunosuppressive Agents;Other: Optimized Supportive Care;Other: Yi-Qi-Qing-Jie herbal compound placebo | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Recruiting | 18 Years | 70 Years | All | 56 | Phase 2/Phase 3 | China | |
| 5 | NCT03841448 | April 24, 2019 | 11 November 2019 | A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN) | A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients With IgA Nephropathy | IgA Nephropathy (IgAN);Berger Disease;Glomerulonephritis, IgA | Drug: Placebo;Drug: Cemdisiran | Alnylam Pharmaceuticals | Recruiting | 18 Years | 65 Years | All | 30 | Phase 2 | United States;Canada;France;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT03945318 | April 8, 2019 | 20 May 2019 | Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN) | A Phase 1, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy | IgA Nephropathy | Drug: BION-1301 Single Dose;Drug: Placebo Single Dose;Drug: BION-1301 Multiple Doses;Drug: Placebo Multiple Doses | Aduro Biotech, Inc. | Recruiting | 18 Years | 55 Years | All | 73 | Phase 1 | United Kingdom | |
| 7 | ChiCTR1900022100 | 2019-04-01 | 1 April 2019 | Evaluation of clinical efficacy of Modified Huangqi Chifeng Decoction in treating IgA Nephropathy proteinuia based on Chinese medicine pathogenesis of “deficiency-wind-stasis -toxin” | Evaluation of clinical efficacy of Modified Huangqi Chifeng Decoction in treating IgA Nephropathy proteinuia based on Chinese medicine pathogenesis of “deficiency-wind-stasis -toxin” | IgA nephropathy | Placebo Group:Placebo+telmisartan;Experimental group:Flavoured huangqi chifeng granules+telmisartan; | Xiyuan Hospital, China Academy of Chinese Medical Sciences | Recruiting | Both | Placebo Group:40;Experimental group:40; | Phase 4 | China | |||
| 8 | NCT03468972 | March 2019 | 25 February 2019 | Effect of Immunosuppression in IgA Nephropathy | Effect of Immunosuppression in IgA Nephropathy | Biopsy-proven IgA Nephropathy | Drug: Immunosuppressive treatment;Other: intensive supportive care | Yonsei University | Not recruiting | 19 Years | 75 Years | All | 174 | Phase 4 | Korea, Republic of | |
| 9 | NCT03762850 | December 20, 2018 | 26 August 2019 | A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy | A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy | Immunoglobulin A Nephropathy | Drug: sparsentan;Drug: irbesartan | Retrophin, Inc. | Recruiting | 18 Years | N/A | All | 280 | Phase 3 | United States;Australia;Belgium;Croatia;Czechia;Estonia;France;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom | |
| 10 | ChiCTR1800019606 | 2018-12-01 | 26 November 2018 | Effect of kunxian capsule and leflunomide on IgA nephropathy | Effect of kunxian capsule and leflunomide on IgA nephropathy | IgA nephropathy | 1:Kun-Xian Capsule;2:Leflunomide; | The First Affiliated Hospital of Chengdu Medical College | Not Recruiting | 15 | 75 | Both | 1:20;2:20; | Post-market | China | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | EUCTR2017-004605-41-CZ | 03/10/2018 | 7 January 2019 | Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN) | A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy | Immunoglobulin A Nephropathy (IgAN) MedDRA version: 20.0 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Sparsentan Product Code: RE-021 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Sparsentan CAS Number: 254740-64-2 Current Sponsor code: RE-021 Other descriptive name: SPARSENTAN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Trade Name: Irbesartan tablets Product Name: over-encapsulated Irbesartan Tablets Pharmaceutical Form: Capsule, hard INN or Proposed INN: Irbesartan CAS Number: 138402-11-6 Other descriptive name: IRBESARTAN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- | Retrophin, Inc. | Authorised | Female: yes Male: yes | 280 | Phase 3 | Portugal;United States;Taiwan;Estonia;Hong Kong;Spain;Lithuania;United Kingdom;Italy;France;Czech Republic;Poland;Belgium;Croatia;Australia;Germany;New Zealand;Korea, Republic of | |||
| 12 | EUCTR2017-004605-41-ES | 27/09/2018 | 26 November 2018 | Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN) | A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy | Immunoglobulin A Nephropathy (IgAN) MedDRA version: 20.0 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Sparsentan Product Code: RE-021 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Sparsentan CAS Number: 254740-64-2 Current Sponsor code: RE-021 Other descriptive name: SPARSENTAN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Trade Name: Irbesartan tablets (Approved in the USA. Reference listed drug Avapro) NDC # 43547-0374-03 Product Name: over-encapsulated 150 mg Irbesartan Tablets Pharmaceutical Form: Capsule, hard INN or Proposed INN: Irbesartan CAS Number: 138402-11-6 Other descriptive name: IRBESARTAN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- | Retrophin, Inc. | Authorised | Female: yes Male: yes | 280 | Phase 3 | Portugal;United States;Estonia;Hong Kong;Spain;Lithuania;Turkey;Italy;United Kingdom;France;Czech Republic;Hungary;Poland;Malaysia;Belgium;Croatia;Australia;Germany;New Zealand;Korea, Republic of | |||
| 13 | NCT03643965 | September 5, 2018 | 27 May 2019 | Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy | A Randomized, Double-blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy at Risk of Progressing to End-stage Renal Disease (NefIgArd) | Primary IgA Nephropathy | Drug: Nefecon;Drug: Placebo oral capsule | Calliditas Therapeutics AB | Recruiting | 18 Years | N/A | All | 450 | Phase 3 | United States;Argentina;Australia;Belarus;Belgium;Canada;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom | |
| 14 | EUCTR2018-000075-33-SK | 21/06/2018 | 27 August 2018 | OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN) | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN) - ARTEMIS-IGAN | IgA nephropathy (IgAN);Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: OMS721 Pharmaceutical Form: Solution for infusion Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use | Omeros Corporation | Authorised | Female: yes Male: yes | 434 | Phase 3 | United States;Hungary;Slovakia;Canada;Spain;Lithuania;Australia | |||
| 15 | EUCTR2017-004902-16-BE | 18/06/2018 | 4 December 2018 | A study in which the safety and efficacy of Nefecon is compared with placebo in patients with primary IgA Nephropathy. | A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd). | Primary IgA nephropathy patients at risk of developing end stage renal disease MedDRA version: 20.0 Level: LLT Classification code 10069341 Term: Berger's disease System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Nefecon Product Code: Nefecon Pharmaceutical Form: Modified-release capsule, hard INN or Proposed INN: BUDESONIDE CAS Number: 51333-22-3 Other descriptive name: Nefecon Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Modified-release capsule, hard Route of administration of the placebo: Oral use | Calliditas Therapeutics AB | Authorised | Female: yes Male: yes | 450 | Phase 3 | United States;Belarus;Taiwan;Greece;Finland;Spain;Turkey;Italy;United Kingdom;France;Czech Republic;Canada;Argentina;Poland;Belgium;Australia;Germany;Korea, Republic of;Sweden | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | EUCTR2018-000075-33-LT | 15/06/2018 | 23 July 2018 | OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN) | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN) - ARTEMIS-IGAN | IgA nephropathy (IgAN);Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: OMS721 Pharmaceutical Form: Solution for infusion INN or Proposed INN: OMS721 Current Sponsor code: OMS721 Other descriptive name: OMS721 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 370- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use | Omeros Corporation | Authorised | Female: yes Male: yes | 434 | Phase 3 | United States;Hungary;Canada;Lithuania;Australia | |||
| 17 | EUCTR2018-000075-33-HU | 07/06/2018 | 18 June 2018 | OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN) | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN) - ARTEMIS-IGAN | IgA nephropathy (IgAN);Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: OMS721 Pharmaceutical Form: Solution for infusion Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use | Omeros Corporation | Authorised | Female: yes Male: yes | 434 | Phase 3 | United States;Hungary;Canada;Australia | |||
| 18 | EUCTR2017-004902-16-CZ | 04/06/2018 | 20 August 2018 | A study in which the safety and efficacy of Nefecon is compared with placebo in patients with primary IgA Nephropathy. | A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd). | Primary IgA nephropathy patients at risk of developing end stage renal disease MedDRA version: 20.0 Level: LLT Classification code 10069341 Term: Berger's disease System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Nefecon Product Code: Nefecon Pharmaceutical Form: Modified-release capsule, hard INN or Proposed INN: BUDESONIDE CAS Number: 51333-22-3 Other descriptive name: Nefecon Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Modified-release capsule, hard Route of administration of the placebo: Oral use | Calliditas Therapeutics AB | Authorised | Female: yes Male: yes | 450 | Phase 3 | United States;Belarus;Taiwan;Greece;Finland;Spain;Turkey;Italy;United Kingdom;France;Czech Republic;Canada;Argentina;Poland;Belgium;Australia;Germany;Korea, Republic of;Sweden | |||
| 19 | EUCTR2017-004902-16-ES | 09/04/2018 | 11 June 2018 | A study in which the safety and efficacy of Nefecon is compared with placebo in patients with primary IgA Nephropathy. | A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd). | Primary IgA nephropathy patients at risk of developing end stage renal disease MedDRA version: 20.0 Level: LLT Classification code 10069341 Term: Berger's disease System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Nefecon Product Code: Nefecon Pharmaceutical Form: Modified-release capsule, hard INN or Proposed INN: BUDESONIDE CAS Number: 51333-22-3 Other descriptive name: Nefecon Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Modified-release capsule, hard Route of administration of the placebo: Oral use | Calliditas Therapeutics AB | Authorised | Female: yes Male: yes | 450 | Phase 3 | United States;Belarus;Taiwan;Greece;Finland;Spain;Turkey;Italy;United Kingdom;France;Czech Republic;Canada;Argentina;Poland;Belgium;Australia;Germany;Korea, Republic of;Sweden | |||
| 20 | JPRN-UMIN000032031 | 2018/04/01 | 5 November 2019 | The steroid internal use method for patients with IgA nephropathy | The steroid internal use method for patients with IgA nephropathy - The steroid internal use method for patients with IgA nephropathy | IgA nephropathy | Prednisolone 0.5mg/kg/every other day group Prednisolone 0.25mg/kg/everyday group | Juntendo University | Recruiting | 20years-old | 100years-old | Male and Female | 100 | Not selected | Japan | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | EUCTR2017-004902-16-SE | 28/03/2018 | 28 February 2019 | A study in which the safety and efficacy of Nefecon is compared with placebo in patients with primary IgA Nephropathy. | A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd). | Primary IgA nephropathy patients at risk of developing end stage renal disease MedDRA version: 20.0 Level: LLT Classification code 10069341 Term: Berger's disease System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Nefecon Product Code: Nefecon Pharmaceutical Form: Modified-release capsule, hard INN or Proposed INN: BUDESONIDE CAS Number: 51333-22-3 Other descriptive name: Nefecon Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Modified-release capsule, hard Route of administration of the placebo: Oral use | Calliditas Therapeutics AB | Authorised | Female: yes Male: yes | 450 | Phase 3 | United States;Belarus;Taiwan;Greece;Finland;Spain;Turkey;Italy;United Kingdom;France;Czech Republic;Canada;Argentina;Poland;Belgium;Australia;Germany;Korea, Republic of;Sweden | |||
| 22 | NCT03188887 | February 20, 2018 | 1 April 2019 | Treatment of IgA Nephropathy According to Renal Lesions | Treatment of IgA Nephropathy According to Renal Lesions | IgA Nephropathy | Drug: corticotherapy;Drug: Renin Angiotensin system (RAS) blockade | Assistance Publique - Hôpitaux de Paris | Recruiting | 18 Years | N/A | All | 122 | Phase 3 | France | |
| 23 | EUCTR2017-000891-27-SE | 19/02/2018 | 22 October 2018 | A study evaluating the of safety and efficacy of LNP023 in patients with a kidney disorder called IgAN nephropathy | An adaptive seamless randomized, double-blind, placebo-controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients | Primary IgA Nephropathy MedDRA version: 20.0 Level: HLGT Classification code 10029149 Term: Nephropathies System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: LNP023 Pharmaceutical Form: Capsule, hard INN or Proposed INN: not yet established Other descriptive name: LNP023 HYDROCHLORIDE SALT Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Code: LNP023 Pharmaceutical Form: Capsule, hard INN or Proposed INN: not yet established Other descriptive name: LNP023 HYDROCHLORIDE SALT Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Code: LNP023 Pharmaceutical Form: Capsule, hard INN or Proposed INN: not yet established Other descriptive name: LNP023 HYDROCHLORIDE SALT Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Novartis Pharma AG | Authorised | Female: yes Male: yes | 218 | Phase 2 | United States;Taiwan;Finland;Thailand;United Kingdom;Argentina;Belgium;Singapore;Australia;Denmark;Netherlands;Germany;Norway;China;Sweden;Korea, Republic of | |||
| 24 | NCT03608033 | February 16, 2018 | 11 June 2019 | Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN) | IgA Nephropathy | Biological: OMS721;Other: Vehicle (D5W or saline) | Omeros Corporation | Recruiting | 18 Years | N/A | All | 450 | Phase 3 | United States;Australia;Austria;Belgium;Bulgaria;Hungary;Lithuania;Poland;Slovakia;Spain | |
| 25 | NCT03373461 | February 7, 2018 | 4 November 2019 | Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation | An Adaptive Seamless Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Investigate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients | IgA Nephropathy | Drug: LNP023;Drug: Placebo | Novartis Pharmaceuticals | Recruiting | 18 Years | N/A | All | 118 | Phase 2 | Argentina;Australia;Belgium;China;Denmark;Finland;Germany;Netherlands;Norway;Singapore;Sweden;Taiwan;Thailand;Turkey;United Kingdom | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | NCT03453619 | January 22, 2018 | 28 January 2019 | Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies | A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease) | IgA Nephropathy;Lupus Nephritis;Membranous Nephropathy;C3 Glomerulonephritis;Dense Deposit Disease | Drug: APL-2 | Apellis Pharmaceuticals, Inc. | Recruiting | 18 Years | N/A | All | 48 | Phase 2 | United States | |
| 27 | EUCTR2017-000891-27-FI | 09/01/2018 | 6 November 2018 | A study evaluating the of safety and efficacy of LNP023 in patients with a kidney disorder called IgAN nephropathy | An adaptive seamless randomized, double-blind, placebo-controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients | Primary IgA Nephropathy MedDRA version: 20.0 Level: HLGT Classification code 10029149 Term: Nephropathies System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: LNP023 Pharmaceutical Form: Capsule, hard INN or Proposed INN: not yet established Other descriptive name: LNP023 HYDROCHLORIDE SALT Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Code: LNP023 Pharmaceutical Form: Capsule, hard INN or Proposed INN: not yet established Other descriptive name: LNP023 HYDROCHLORIDE SALT Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Code: LNP023 Pharmaceutical Form: Capsule, hard INN or Proposed INN: not yet established Other descriptive name: LNP023 HYDROCHLORIDE SALT Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Novartis Pharma AG | Authorised | Female: yes Male: yes | 218 | Phase 2 | United States;Taiwan;Finland;Thailand;United Kingdom;Argentina;Belgium;Singapore;Australia;Denmark;Netherlands;Germany;Norway;China;Sweden;Korea, Republic of | |||
| 28 | ChiCTR-IIR-17013487 | 2018-01-01 | 27 November 2017 | A multicenter, double blind, double dummy, randomized controlled clinical study on the treatment of IgA nephropathy with Zhengqingfengtongning extantab | A multicenter, double blind, double dummy, randomized controlled clinical study on the treatment of IgA nephropathy with Zhengqingfengtongning extantab | IgA nephropathy | Experimental group:Zhengqing Fengtongning extantab;Control group 1:Losartan Potassium Tablets;Control group 2:Losartan Potassium Tablets + Zhengqing Fengtongning extantab; | The Third Xiangya Hospital of Central South University | Recruiting | 18 | 70 | Both | Experimental group:36;Control group 1:36;Control group 2:36; | Phase 4 study | China | |
| 29 | NCT03366337 | December 26, 2017 | 24 June 2019 | A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX | A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases | IgA Nephropathy;CKD Associated With Type 1 Diabetes;Focal Segmental Glomerulosclerosis;Autosomal Dominant Polycystic Kidney | Drug: Bardoxolone methyl capsules | Reata Pharmaceuticals, Inc. | Not recruiting | 18 Years | 65 Years | All | 103 | Phase 2 | United States | |
| 30 | NCT03633864 | November 22, 2017 | 3 September 2018 | Fecal Microbiota Transplantation for Refractory IgA Nephropathy | Fecal Microbiota Transplantation for Refractory IgA Nephropathy: a Prospective, Single-center, Cohort Study | IgA Nephropathy | Biological: Fecal microbiota transplantation | Fourth Military Medical University | Recruiting | 18 Years | 65 Years | All | 30 | Phase 2 | China | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | EUCTR2016-002262-31-GB | 17/03/2017 | 11 December 2017 | A Clinical Trial to Examine the Effects of the Drug Atacicept in Patients with Nephropathy (Diabetic Kidney Disease). | A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy | IgA Nephropathy MedDRA version: 20.1 Level: PT Classification code 10061835 Term: Diabetic nephropathy System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 20.0 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Atacicept Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Atacicept Other descriptive name: ATACICEPT Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 25-150 Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use | Merck KGaA | Authorised | Female: yes Male: yes | 50 | Phase 2 | France;United States;Czech Republic;Taiwan;Belgium;Spain;Singapore;Israel;Japan;Italy;United Kingdom;Korea, Republic of | |||
| 32 | JPRN-JapicCTI-183956 | 21/2/2017 | 10 September 2019 | A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy | A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy | IgA Nephropathy | Intervention name : Atacicept25mg INN of the intervention : Atacicept Dosage And administration of the intervention : Subject will receive Atacicept 25 milligram (mg) once weekly as a subcutaneous (SC) injection for 72 weeks. Intervention name : Atacicept75mg INN of the intervention : Atacicept Dosage And administration of the intervention : Subject will receive Atacicept 75 mg once weekly as an SC injection for 72 weeks. Intervention name : Atacicept25mg INN of the intervention : Atacicept Dosage And administration of the intervention : Subject will receive Atacicept 25 mg once weekly as an SC injection for 156 weeks. Intervention name : Atacicept75mg INN of the intervention : Atacicept Dosage And administration of the intervention : Subject will receive Atacicept 75 mg once weekly as an SC injection for 156 weeks. Intervention name : Atacicept150mg INN of the intervention : Atacicept Dosage And administration of the intervention : Subject will receive Atacicept 150 mg once weekly as an SC injection for 156 weeks. Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : Subject will receive matching Placebo to atacicept once weekly as an SC injection for 72 weeks. Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : Subject will receive matching Placebo to atacicept once weekly as an SC injection for 156 weeks. | Merck Biopharma Co., Ltd. | Not Recruiting | 20 | BOTH | 60 | Phase 2 | Japan, Europe | ||
| 33 | NCT02808429 | January 31, 2017 | 11 June 2019 | Efficacy and Safety of Atacicept in IgA Nephropathy | A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy | IgA Nephropathy | Drug: Atacicept 25 mg;Drug: Atacicept 75 mg;Drug: Placebo;Drug: Atacicept 150 mg | EMD Serono Research & Development Institute, Inc. | Merck KGaA, Darmstadt, Germany | Not recruiting | 18 Years | N/A | All | 30 | Phase 2 | United States;Japan;United Kingdom;Germany |
| 34 | EUCTR2016-004507-31-FR | 27/01/2017 | 8 January 2018 | N/A | N/A - TIGER | MedDRA version: 19.1 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders | Trade Name: METHYLPREDNISOLONE MYLAN Générique Product Name: METHYLPREDNISOLONE MYLAN Générique Pharmaceutical Form: Powder for injection INN or Proposed INN: Methylprednisolone Other descriptive name: Methylprednisolone Concentration unit: mg/kg milligram(s)/kilogram Concentration type: range Trade Name: PREDNISONE ARROW 20mg Product Name: PREDNISONE ARROW 20mg Pharmaceutical Form: Tablet INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Concentration unit: mg milligram(s) Concentration type: equal Trade Name: PREDNISONE ARROW 5 mg Product Name: PREDNISONE ARROW 5 mg Pharmaceutical Form: Tablet INN or Proposed INN: Prednisone 5 mg Other descriptive name: Prednisone 5 mg Concentration unit: mg milligram(s) Concentration type: equal | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | Authorised | Female: yes Male: yes | 122 | Phase 3 | France | |||
| 35 | ChiCTR-IOR-16010174 | 2016-12-01 | 18 April 2017 | Clinical Study on Treatment of spleen and kidney Yang deficiency type of IgA nephropathy proteinuria with 'Huangqi guizhi wuwu' decoction | Clinical Study on Treatment of spleen and kidney Yang deficiency type of IgA nephropathy proteinuria with 'Huangqi guizhi wuwu' decoction | IgA nephropathy | Basic treatment+Valsartan Capsules treatment group:Basic treatment+Valsartan Capsules treatment ;Basic treatment+Huangqi guizhi wuwu decoction treatment group:Basic treatment+Huangqi guizhi wuwu decoction treatment; | Shuguang Hospital affliliated to Shanghai Univesrity of TCM | Recruiting | 18 | 65 | Both | Basic treatment+Valsartan Capsules treatment group:50;Basic treatment+Huangqi guizhi wuwu decoction treatment group:50; | Other | China | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | NCT03218852 | December 2016 | 16 December 2017 | Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy | An Extended Follow-up of the Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced Stage IgA Nephropathy | IgA Nephropathy | Drug: prednisone and cyclophosphamide;Drug: prednisone alone | Guangdong General Hospital | Not recruiting | 18 Years | 70 Years | All | 133 | Phase 4 | China | |
| 37 | NCT02942381 | September 13, 2016 | 12 February 2018 | A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy | IgA Patients;Hydroxychloroquine | Drug: Hydroxychloroquine Sulfate;Drug: Placebo | Peking University First Hospital | Not recruiting | 18 Years | 75 Years | All | 60 | Phase 2 | China | ||
| 38 | NCT02712697 | June 2016 | 11 April 2016 | Integrative Medicine of IgA Nephropathy | Treatment of Shentong Granules Plus Prednisone on Patients With Severe IgA Nephropathy(Ying-deficiency of the Liver and Kidney Pattern): a Randomized, Double-blind,Placebo-controlled Multicentre Clinical Trial | Primary IgA Nephropathy | Drug: WM (Shentong Granules);Drug: Hormone (prednisone) | Shanghai University of Traditional Chinese Medicine | RenJi Hospital;Ruijin Hospital;Shanghai 6th People's Hospital;Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;Fudan University | Not recruiting | 18 Years | 70 Years | Both | 140 | N/A | China |
| 39 | NCT02765594 | June 2016 | 16 December 2017 | Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy | Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study | Primary IgA Nephropathy | Drug: Hydroxychloroquine Sulfate;Drug: Valsartan | Peking Union Medical College Hospital | Recruiting | 18 Years | 60 Years | All | 98 | Phase 4 | China | |
| 40 | NCT02981212 | June 2016 | 12 December 2016 | Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy | Multi-center, Randomized, Open Label, Comparative, Phase IV Study to Evaluate the Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid for 48 Weeks in Advanced IgA Nephropathy | IgA Nephropathy | Drug: Mycophenolate Mofetil;Drug: ACE inhibitor;Drug: Corticosteroid;Drug: ARB | Yonsei University | Chong Kun Dang Pharmaceutical Corp.;Kyung Hee University Hospital at Gangdong;Kyungpook National University;Pusan National University Yangsan Hospital;Inje University;Seoul St. Mary's Hospital;Chonbuk National University Hospital | Recruiting | 19 Years | 65 Years | Both | 100 | Phase 4 | Korea, Republic of |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | NCT02662283 | May 2016 | 15 February 2016 | Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy | Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy —— A Prospective, Randomized, Controlled, Multi-Center Clinical Trial | IGA Nephropathy | Drug: Prednisolone;Drug: Reh-acteoside | Sun Yat-sen University | Not recruiting | 14 Years | 70 Years | Both | 75 | Phase 2/Phase 3 | China | |
| 42 | NCT02647255 | March 2016 | 10 September 2018 | Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy | Randomized Trial of Plasma Exchange as Adjunctive Therapy for Severe Crescentic GlomerUlonephritis of IgA NEphropathy (RESCUE Study) | Glomerulonephritis, IGA;Kidney Diseases;Acute Renal Insufficiency;Rapidly Progressive Glomerulonephritis | Procedure: Plasma Exchange (PE);Drug: Methylprednisolone pulse | Peking University First Hospital | Recruiting | 14 Years | 65 Years | All | 150 | Phase 2/Phase 3 | China | |
| 43 | NCT02682407 | February 2016 | 22 January 2018 | Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 | A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease | IgAN;Lupus Nephritis;MN;C3G | Biological: OMS721;Other: Vehicle (D5W) | Omeros Corporation | Recruiting | 18 Years | N/A | All | 44 | Phase 2 | United States | |
| 44 | NCT03015974 | January 2016 | 28 January 2019 | Registry of IgA Nephropathy in Chinese Children | Registry of IgA Nephropathy in Chinese Children | IgA Nephropathy;Proteinuria in Nephrotic Range;Immunosuppressive Treatment | Drug: Corticosteroid;Drug: Cyclophosphamide;Drug: Mycophenolate mofetil;Drug: Dipyridamole;Drug: ACE Inhibitor or Angiotensin receptor antagonist | Peking University First Hospital | Nanjing PLA General Hospital;Beijing Children's Hospital;Central South University;The Children's Hospital of Zhejiang University School of Medicine;First Affiliated Hospital, Sun Yat-Sen University;Tongji Hospital;Hunan Children's Hospital;Shanghai Children's Hospital;Nanjing Children's Hospital;Children's Hospital of Chongqing Medical University;Shandong Provincial Hospital;Fuzhou General Hospital;Second Affiliated Hospital of Wenzhou Medical University;Children's Hospital of Hebei Province;Guangzhou Women and Children's Medical Center;Jiangxi Province Children's Hospital;Guangzhou First People's Hospital;Xian Children's Hospital;Capital Institute of Pediatrics, China;First Hospital of Jilin University;Wuhan Women and Children's Medical Center;Tianjin Children's Hospital;Chengdu Women's and Children's Central Hospital;The First People's Hospital of Yunnan | Recruiting | 1 Month | 18 Years | All | 1200 | Phase 3 | China |
| 45 | NCT02605525 | December 2015 | 16 December 2017 | Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy | A Phase 2 Study to Assess the Efficacy and Safety of Intravenous Infusion With Human Soluble Recombinant Fc-gamma Receptor IIB (SM101/BAX 1810) in Subjects With Immunoglobulin A Nephropathy (IgAN) | Immunoglobulin A Nephropathy | Biological: SM101;Other: Placebo | Baxalta now part of Shire | Not recruiting | 18 Years | N/A | All | 0 | Phase 2 | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | EUCTR2015-002345-64-CZ | 12/11/2015 | 14 March 2016 | Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy | A Phase 2 Study to Assess the Efficacy and Safety of Intravenous Infusion with Human Soluble Recombinant Fc-gamma Receptor IIB (SM101/BAX 1810) in Subjects with Immunoglobulin A Nephropathy (IgAN) - Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy | IgA Nephropathy MedDRA version: 18.0 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Body processes [G] - Immune system processes [G12] | Product Code: SM101 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Not available Current Sponsor code: SM101 Other descriptive name: human soluble recombinant Fc-gamma receptor IIB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use | Baxalta Innovations GmbH | Not Recruiting | Female: yes Male: yes | 51 | Phase 2 | United States;Hong Kong;Czech Republic;Canada;Belgium;Denmark;Germany;United Kingdom;Sweden | |||
| 47 | NCT02433236 | September 2015 | 2 November 2015 | Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy | A Phase 2, Multi-Centre, Open Label Extension Study of Fostamatinib in the Treatment of IgA Nephropathy for Patients Who Participated in Study C-935788-050 | IGA Nephropathy | Drug: Fostamatinib Disodium tablet 150 mg;Drug: Fostamatinib Disodium tablet 100 mg | Rigel Pharmaceuticals | Not recruiting | 18 Years | 72 Years | Both | 0 | Phase 2 | ||
| 48 | ChiCTR-IPR-15006760 | 2015-08-07 | 18 April 2017 | Efficacy and Safety of Tacrolimus in the Treatment of Immunogloglumin A Nephropathy: a Glucocorticoids-controlled, multicenter, randomized, open label clinical study | Efficacy and Safety of Tacrolimus in the Treatment of Immunogloglumin A Nephropathy: a Glucocorticoids-controlled, multicenter, randomized, open label clinical study | IgA nephropathy | Tacrolimus Group :Tacrolimus;Glucocorticoids Group :Glucocorticoids; | Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University | Not Recruiting | 18 | 65 | Both | Tacrolimus Group :90;Glucocorticoids Group :90; | Post-market | China | |
| 49 | NCT02282930 | March 2015 | 4 March 2019 | Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression | An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression | Progressive IgA Nephropathy;Proteinuria | Drug: ACTH (Acthar) Gel | Mayo Clinic | Mallinckrodt | Not recruiting | 18 Years | N/A | All | 10 | Phase 3 | United States |
| 50 | EUCTR2014-003402-33-SE | 12/02/2015 | 26 February 2018 | An open-label phase 2 study to evaluate the safety and efficacy of CCX168 in subjects with IgA Nephropathy on stable RAAS blockade. | An open-label phase 2 study to evaluate the safety and efficacy of CCX168 in subjects with IgA Nephropathy on stable RAAS blockade. | IgAN is reported as the most common glomerulonephritis worldwide. It is associated with a wide spectrum of disease severity and rate of progression of renal failure. MedDRA version: 17.1 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: CCX168 Pharmaceutical Form: Capsule, hard Current Sponsor code: CCX168 Other descriptive name: CCX168 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10mg per capsule- | ChemoCentryx, Inc. | Not Recruiting | Female: yes Male: yes | 20 | Phase 2 | United States;Belgium;Sweden | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 51 | EUCTR2014-003402-33-BE | 09/02/2015 | 23 January 2017 | An open-label phase 2 study to evaluate the safety and efficacy of CCX168 in subjects with IgA Nephropathy on stable RAAS blockade. | An open-label phase 2 study to evaluate the safety and efficacy of CCX168 in subjects with IgA Nephropathy on stable RAAS blockade. | IgAN is reported as the most common glomerulonephritis worldwide. It is associated with a wide spectrum of disease severity and rate of progression of renal failure. MedDRA version: 17.1 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: CCX168 Pharmaceutical Form: Capsule, hard Current Sponsor code: CCX168 Other descriptive name: CCX168 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10mg per capsule- | ChemoCentryx, Inc. | Not Recruiting | Female: yes Male: yes | 20 | Phase 2 | United States;Belgium;Sweden | |||
| 52 | NCT02382523 | February 2015 | 16 December 2017 | Acthar on Proteinuria in IgA Nephropathy Patients | Impact of Acthar on Proteinuria and Disease Progression in IgA Nephropathy Patients With Nephrotic Range Proteinuria | IgA Nephropathy;Proteinuria | Drug: Acthar 80 unit injection | Baylor College of Medicine | Not recruiting | 18 Years | N/A | All | 0 | Phase 4 | United States | |
| 53 | NCT02351752 | January 2015 | 28 December 2015 | Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study | Renal Division, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease | Primary IgA Nephropathy | Drug: Hydroxychloroquine Sulfate | LLiu | Not recruiting | 18 Years | 75 Years | Both | 20 | Phase 4 | China | |
| 54 | NCT02052219 | October 2014 | 10 August 2015 | BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy | A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy | IgA Nephropathy | Drug: Blisibimod;Drug: Placebo | Anthera Pharmaceuticals | Not recruiting | 18 Years | N/A | Both | 0 | Phase 3 | ||
| 55 | NCT02112838 | October 2014 | 28 January 2019 | Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy | A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy | IGA Nephropathy | Drug: Fostamatinib 150 mg;Drug: Fostamatinib 100 mg;Drug: Placebo | Rigel Pharmaceuticals | Not recruiting | 18 Years | 70 Years | All | 76 | Phase 2 | United States;Austria;Germany;Hong Kong;Taiwan;United Kingdom;Singapore;Switzerland | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 56 | NCT03719443 | September 25, 2014 | 22 October 2019 | First in Human Study to Assess Safety of VIS649 in Healthy Subjects | A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of VIS649 Administered Intravenously in Healthy Subjects | Immunoglobulin A Nephropathy;IgAN - IgA Nephropathy;IgA Nephropathy | Biological: VIS649;Biological: Placebo | Visterra, Inc. | Not recruiting | 18 Years | 55 Years | All | 41 | Phase 1 | United States | |
| 57 | NCT02231125 | September 2014 | 21 July 2016 | Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy | Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial | IgA Nephropathy | Drug: Losartan;Drug: Abelmoschus manihot | Chen Xiangmei | Jiangsu Suzhong Pharmaceutical Group Co., Ltd. | Recruiting | 18 Years | 65 Years | Both | 1600 | Phase 4 | China |
| 58 | NCT02160132 | June 2014 | 16 March 2015 | A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes. | Effect and Security of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial. | Glomerulonephritis, IGA;Peripapillary Crescent;Necrosis;Steroid Nephropathy | Drug: Methylprednisolone(intravenously in the 1st-2nd-3rd month );Drug: Methylprednisolone(intravenously in the 1st-3rd-5th month) | Sun Yat-sen University | Recruiting | 14 Years | 65 Years | Both | 180 | Phase 2 | China | |
| 59 | NCT02187900 | June 2014 | 19 February 2015 | Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f. | Phase 3 Study of Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f | IgA Nephropathy | Drug: Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH);Drug: Mycophenolate mofetil (MMF) | Second Xiangya Hospital of Central South University | Recruiting | 16 Years | 65 Years | Both | 300 | Phase 3 | China | |
| 60 | NCT01854814 | July 2013 | 8 January 2018 | The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy Patients | The Effects of Mycophenolate Mofetil on Renal Outcomes in Patients With Advanced IgA Nephropathy: a Randomized Open-label Study | IgA Nephropathy | Drug: Mycophenolate mofetil;Drug: Losartan | Fan Fan Hou | Recruiting | 16 Years | 70 Years | All | 232 | N/A | China | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 61 | NCT02062684 | June 2013 | 16 December 2017 | BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy | IgA Nephropathy | Drug: Blisibimod;Drug: Placebo | Anthera Pharmaceuticals | Not recruiting | 18 Years | 65 Years | All | 57 | Phase 2/Phase 3 | Czechia;Germany;Hong Kong;Korea, Republic of;Malaysia;Philippines;Singapore;Taiwan;Thailand;United Kingdom;Canada;Czech Republic;Italy;Russian Federation;Spain | |
| 62 | ChiCTR-TRC-13003038 | 2013-01-01 | 18 April 2017 | Mizoribine for the Treatment of Pediatric IgA Nephropathy | Mizoribine for the Treatment of Pediatric IgA Nephropathy with Moderate Proteinuria--An open, prospective, random, multicenter study | IgA nephropathy | MZR:mizoribine tablet 4 mg/kg a day (not more than 150 mg/d), qd, po + Dipyridamole, 3 mg/kg a day (not more than 25 mg at a time), tid, po;CVT:Lotensin, 0.2 mg/kg a day (not more than 10 mg/d), qd, po + + Dipyridamole, 3 mg/kg a day (not more than 25 mg at a time), tid, po; | Peking University First Hospital | Not Recruiting | 6 | 18 | Both | MZR:60;CVT:60; | Post-market | China | |
| 63 | NCT01781312 | January 2013 | 19 February 2015 | Probiotics in IgA Nephropathy | Proof-of-concept Study of Efficacy and Safety of Dietary Supplementation With Probiotics in IgAN Patients | IgA Nephropathy | Dietary Supplement: ProTectis;Dietary Supplement: Gastrus | Uppsala University Hospital | University Hospital, Linkoeping;Karolinska Institutet | Not recruiting | 18 Years | N/A | Both | 20 | N/A | Sweden |
| 64 | NCT01738035 | December 2012 | 6 October 2015 | The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease | A Multicentre, Interventional Treatment, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon in Primary IgA Nephropathy Patients at Risk of End-stage Renal Disease | Primary IgA Nephropathy | Drug: NEFECON;Other: Placebo | Pharmalink AB | Not recruiting | 18 Years | N/A | Both | 150 | Phase 2 | Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom | |
| 65 | NCT01758120 | December 2012 | 16 December 2017 | Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy | A Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy | IgA Nephropathy | Drug: prednisone plus cyclophosphamide;Drug: Prednisone alone | Guangdong General Hospital | Not recruiting | 18 Years | 70 Years | All | 135 | Phase 4 | China | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 66 | EUCTR2012-001923-11-FI | 17/10/2012 | 4 August 2015 | A study to assess if two different doses of Nefecon (budesonide) compared to placebo are safe and effective in patients with primary IgA nephropathy at risk of developing end-stage renal disease | A Multicentre, Interventional Treatment, Randomised, Double-Blind, Single Group Assignment, Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon® in Primary IgA Nephropathy Patients at Risk of Developing End-Stage Renal Disease - The NEFIGAN Trial | Primary IgA nephropathy patients at risk of developing end stage renal disease MedDRA version: 17.1 Level: LLT Classification code 10069341 Term: Berger's disease System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Nefecon Pharmaceutical Form: Modified-release capsule, hard INN or Proposed INN: BUDESONIDE CAS Number: 51333-22-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Modified-release capsule, hard Route of administration of the placebo: Oral use | Pharmalink AB | Not Recruiting | Female: yes Male: yes | 200 | Czech Republic;Finland;Spain;Belgium;Denmark;Netherlands;Germany;United Kingdom;Italy;Sweden | ||||
| 67 | ChiCTR-TRC-12002228 | 2012-06-15 | 18 April 2017 | The Clinical Study on the Dispelling Wind-dampness of IgA Nephropathy | The Clinical Study on the Dispelling Wind-dampness of the chronic nephropathy: The Clinical Study on the Dispelling Wind-dampness of IgA Nephropathy(Multi-center, double-blind, randomized, controlled clinical trial program) | IgA Nephropathy | Treatment group:IgA nephropathy side (granules)+TWP tablet;Control group:Chinese medicine simulation granules + The Tripterygium simulation piece; | Hangzhou Hospital of Traditional Chinese Medicine | Not Recruiting | 16 | 65 | Both | Treatment group:114;Control group:114; | Other | China | |
| 68 | NCT01560052 | April 2012 | 11 March 2019 | Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study) | Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study Low Dose Study | IgA Glomerulonephritis | Drug: methylprednisolone;Drug: Placebo | The George Institute | Peking University First Hospital | Recruiting | 18 Years | N/A | All | 500 | N/A | Australia;Canada;China;Hong Kong;India;Malaysia |
| 69 | NCT02526966 | March 2012 | 16 December 2017 | Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA Nephropathy | Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA Nephropathy | IgA Nephropathy | Biological: blood sample | Centre Hospitalier Universitaire de Saint Etienne | Not recruiting | 18 Years | N/A | All | 68 | N/A | France | |
| 70 | NCT02571842 | January 2012 | 19 October 2015 | Rituximab in Recurrent IgA Nephropathy | A Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropathy With Active Endocapillary Proliferation Pathology | Recurrent IgA Nephropathy | Drug: Intravenous Rituximab;Drug: ACEI/ARB and corticosteroids | Chulalongkorn University | Recruiting | 18 Years | 70 Years | Both | 30 | Phase 4 | Thailand | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 71 | NCT01237028 | March 2011 | 19 September 2016 | Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System Blockers | Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System Blockers | IgA Nephropathy | Drug: Calcitriol | Yonsei University | Not recruiting | 20 Years | 70 Years | Both | 168 | N/A | Korea, Republic of | |
| 72 | NCT01451710 | March 2011 | 19 February 2015 | The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy | The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy | IgA Nephropathy | Drug: Prednisone or Prednisolone | Nanjing University School of Medicine | Not recruiting | 18 Years | 65 Years | Both | 30 | N/A | China | |
| 73 | ChiCTR-ONC-10001124 | 2011-01-01 | 18 April 2017 | The effect and safety of mizoribine for IgA Nephropathy in children | The effect and safety of mizoribine for IgA Nephropathy in children | IgA nephropathy | 1:mizoribine 3~5mg/kg.d; | Nanjing general hospital of Nanjing military command | Not Recruiting | 5 | 16 | Both | 1:30; | Post-market | China | |
| 74 | ChiCTR-OPN-16010028 | 2011-01-01 | 18 April 2017 | Effects of Tripterygium wilfordii induction therapy to IgA nephropathy patients with heavy proteinuria | Effects of Tripterygium wilfordii induction therapy to IgA nephropathy patients with heavy proteinuria | IgA nephropathy | Prednisone (PRE) group:1mg/kg prednisone once daily;conventional-dose TW (CTW) group:60 mg TW daily;double-dose TW (DTW) group:?????120mg; | Yancheng Third People's Hospital | Not Recruiting | 21 | 54 | Both | Prednisone (PRE) group:10;conventional-dose TW (CTW) group:10;double-dose TW (DTW) group:10; | Post-market | ||
| 75 | NCT02523768 | January 2011 | 5 November 2018 | Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment | Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment | Glomerulonephritis;IgAN | Drug: ATG-F;Drug: Simulect | Centre Hospitalier Universitaire de Saint Etienne | Not recruiting | 18 Years | 75 Years | All | 115 | Phase 4 | France | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 76 | NCT01224028 | November 2010 | 19 February 2015 | A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients | Double-blind, Randomized Placebo-controlled Clinical Trial for the Efficacy and Safety of a Calcineurin Inhibitor, Tacrolimus(Prograf Cap®) in Patients With Non-nephrotic Albuminuric, Normotensive IgA Nephropathy | IgA Nephropathy | Drug: Placebo;Drug: Tacrolimus | Astellas Pharma Inc | Astellas Pharma Korea, Inc. | Not recruiting | 18 Years | 70 Years | Both | 40 | Phase 2 | Korea, Republic of |
| 77 | NCT01269021 | November 2010 | 11 April 2016 | An Multi-site Prospective Study to Assess the Efficacy and Safety of MMF in the Treatment of Proliferative IgA Nephropathy(IgAN) | Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China. | IgA Nephropathy (IgAN) | Drug: mycophenolate mofetil plus lower dose of Prednisone;Drug: Prednisone in full dose | Zhi-Hong Liu, M.D. | Not recruiting | 18 Years | 60 Years | Both | 176 | N/A | China | |
| 78 | NCT01203007 | September 2010 | 19 February 2015 | Diet Intervention in Food Sensitive Patients With IgA Nephropathy | A Pilot Study of 6 Months Diet Intervention in Food Sensitive Patients With IgA Nephropathy | IGA Nephropathy | Dietary Supplement: Tailored diet;Dietary Supplement: Low antigen content diet | Uppsala University Hospital | University Hospital, Linkoeping;Haukeland University Hospital;Smerud Medical Research International AS | Not recruiting | 18 Years | N/A | Both | 40 | N/A | Norway;Sweden |
| 79 | NCT01103778 | July 2010 | 11 June 2018 | Pilot Study of Velcade® in IgA Nephropathy | Velcade Therapy for Severe IgA Nephropathy | Chronic Kidney Disease;IgA Nephropathy | Drug: Bortezomib (Velcade®) | The Rogosin Institute | Weill Medical College of Cornell University | Not recruiting | 18 Years | N/A | All | 11 | Phase 4 | United States |
| 80 | NCT01184599 | June 2010 | 19 February 2015 | A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy | Glomerulonephritis, IGA;Hypertension | Drug: aliskiren | Kagawa University | Recruiting | 16 Years | 75 Years | Both | 30 | Phase 4 | Japan | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 81 | EUCTR2009-016003-26-GB | 06/05/2010 | 20 March 2012 | RANDOMISED PILOT TRIAL OF MYFORTIC FOR THE TREATMENT OF PRIMARY PROTEINURIC GLOMERULONEPHRITIS. - GloMY - Proteinuria in glomerulonephritis : Myfortic | RANDOMISED PILOT TRIAL OF MYFORTIC FOR THE TREATMENT OF PRIMARY PROTEINURIC GLOMERULONEPHRITIS. - GloMY - Proteinuria in glomerulonephritis : Myfortic | Primary Proteinuric Glomeruolnephritis Focal segmental glomeruloscerosis and IgA nephropathy MedDRA version: 14.1 Level: PT Classification code 10067757 Term: Focal segmental glomerulosclerosis System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders | Trade Name: Myfortic Product Name: Myfortic 360mg Tablets Pharmaceutical Form: Gastro-resistant tablet INN or Proposed INN: mycophenolic acid CAS Number: 24280-93-1 Other descriptive name: mycophenolate sodium Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 360- Trade Name: Myfortic Product Name: Myfortic 180mg Tablets Pharmaceutical Form: Gastro-resistant tablet INN or Proposed INN: mycophenolic sodium CAS Number: 24280-93-1 Other descriptive name: mycophenolate sodium Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 180- Product Name: Prednisolone Pharmaceutical Form: Tablet INN or Proposed INN: prednisolone CAS Number: 50-24-8 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 1.0-25.0 | UHB NHS Foundation Trust | Authorised | Female: yes Male: yes | 100 | United Kingdom | ||||
| 82 | ChiCTR-TRC-10000776 | 2010-02-27 | 18 April 2017 | A Study on the Efficacy and Safety of Telmisartan, Clopidogrelin and Leflunomide in patients with IgA nephropathy | A Study on the Efficacy and Safety of Telmisartan, Clopidogrelin and Leflunomide in patients with IgA nephropathy | lgA nephropathy;ICD:N03.8 | 1:Telmisartan+ Clopidogrelin placebo + Leflunomide placebo ;2:Telmisartan + Clopidogrelin+ Leflunomide placebo ;3:Telmisartan + Clopidogrelin placebo + Leflunomide;4:Telmisartan + Clopidogrelin + Leflunomide; | Chinese General Hospital of PLA | Not Recruiting | 18 | 55 | Both | 1:100;2:100;3:100;4:100; | Post-market | China | |
| 83 | ChiCTR-TRC-10000824 | 2010-01-01 | 18 April 2017 | the clinical effect of Fufang Shenyan Tablet on IgA Nephropathy patients | Multicenter, randomized, double-blind, placebo-controlled clinical research of the clinical effect of Fufang Shenyan Tablet on IgA Nephropathy patients | IgA Nephropathy | the control group:The 24-hour urinary protein 0.5-2.0g: Lotensin 10mg, bid; placebos 2.5g tid; The 24-hour urinary protein 2.0-3.5g: on this basis, combined with prednisone 40mg/d; If patients with hypertension(target blood pressure <=130/80mmHg), used Lotensin 10mg bid alone control it difficultly, give Norvasc 5mg, qd~bid instead; if still poorly controlled, combined with Betaloc 12.5mg, bid;the treatment group:The 24-hour urinary protein 0.5-2.0g: Lotensin 10mg, bid; Fufang Shenyan Tablets 2.5g tid; The 24-hour urinary protein 2.0-3.5g: on this basis, combined with prednisone 40mg/d; If patients with hypertension (target blood pressure <=130/80mmHg), used Lotensin 10mg bid alone control it difficultly, give Norvasc 5mg, qd~bid instead; if still poorly controlled, combined with Betaloc 12.5mg, bid; | The First Affiliated Hospital of Xi'an Jiaotong University Medical College | Not Recruiting | 18 | 65 | Both | the control group:60;the treatment group:60; | Post-market | China | |
| 84 | ChiCTR-TRC-13003702 | 2010-01-01 | 18 April 2017 | Study of Standardized Treatment of Integrative Medicine With the Severe IgA Nephropathy | Study of Standardized Treatment of Integrative Medicine With the Severe IgA Nephropathy | IgA Nephropathy | Experimental Group:Chinese Herb Prescription Granule, 6g, Bid, po. 48 weeks;Placebo Comparator:Placebo of Chinese Herb Prescription Granule, 6g, Bid, po. 48 weeks plus prednisone, 0.5mg-1mg/kg/d, po. 48 weeks; | Department of Nephrology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine | Not Recruiting | 18 | 60 | Both | Experimental Group:100;Placebo Comparator:10; | Other | China | |
| 85 | NCT01879514 | January 2010 | 19 February 2015 | Study of Standardized Treatment of Integrative Medicine With the Severe IgA Nephropath | Study of Standardized Treatment of Integrative Medicine With the Severe IgA Nephropath | IgA Nephropathy | Drug: Chinese Herb Prescription Granule plus prednisone;Drug: Placebo | Shanghai University of Traditional Chinese Medicine | Shanghai Sixth People's Hospital;RenJi Hospital | Recruiting | 18 Years | 60 Years | Both | 200 | N/A | China |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 86 | JPRN-UMIN000002887 | 2009/12/01 | 2 April 2019 | A multicenter study to examine renal protection by a combination of an HMG-CoA reductase inhibitor and losartan in patients with dyslipidemia associated with IgA nephropathy | IgA nephropathy | statin and losartan group: simvastatin 5mg and Losartan 50mg/day more than 3 months statin group: simvastatin 5mg/day more than 3 months | Fukuoka University Faculty of Medicine | Recruiting | 20years-old | Not applicable | Male and Female | 80 | Not selected | Japan | ||
| 87 | NCT01129557 | September 2009 | 19 October 2017 | Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease | Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease | Proteinuric Kidney Disease;Diabetic Nephropathy;Hypertensive Nephrosclerosis;IgA Nephropathy;Focal Segmental Glomerulosclerosis;Glomerulopathy (Obesity-associated);Glomerulonephritis, Membranous | Drug: Aliskiren;Drug: Valsartan | Columbia University | Novartis Pharmaceuticals | Not recruiting | 18 Years | N/A | All | 46 | Phase 4 | United States |
| 88 | NCT00922311 | July 2009 | 3 August 2015 | Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade | Aliskiren Combined With Losartan in Immunoglobulin A Nephropathy: an Open-label Pilot Study | IgA Nephropathy | Drug: Aliskiren | The University of Hong Kong | Queen Mary Hospital, Hong Kong;United Christian Hospital | Not recruiting | 18 Years | 70 Years | Both | 25 | Phase 4 | China |
| 89 | ChiCTR-TRC-09000338 | 2009-04-01 | 18 April 2017 | Full dose of RASS blockade versus steroids therapy in patients with IgA nephropathy | Full dose of RASS blockade versus steroids therapy in patients with IgA nephropathy | IgA nephropathy | Group A:Full dose of RASS blockade (ACEI and ARB blocker);Group B:prednisone ; | The First Affiliated Hospital of Zhejiang University | Not Recruiting | 18 | 70 | Male | Group A:60;Group B:60; | Post-market | China | |
| 90 | NCT00870493 | April 2009 | 19 February 2015 | Aliskiren for Immunoglobulin A (IgA) Nephropathy | The Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over Study | IgA Nephropathy | Drug: Aliskiren;Drug: Placebo | Chinese University of Hong Kong | Not recruiting | 18 Years | 65 Years | Both | 22 | Phase 3 | Hong Kong | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 91 | NCT00856674 | March 2009 | 19 February 2015 | Safety Study of of Intravenous CCL2-LPM in Patients With IgA Nephropathy | A Dose-Escalating Phase I Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous OPL-CCL2-LPM in Patients With IgA Nephropathy | IGA Nephropathy;Proteinuria | Biological: OPL-CCL2-LPM | Osprey Pharmaceuticals USA, Inc. | Not recruiting | 18 Years | N/A | Both | 30 | Phase 1 | Canada | |
| 92 | NCT00885547 | March 2009 | 13 April 2015 | Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis | Prospective Clinical Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis. | IgA Nephropathy | Drug: tripterygium wilfordii (TW) | Nanjing University School of Medicine | Not recruiting | 18 Years | 60 Years | Both | 90 | N/A | China | |
| 93 | NCT00498368 | February 2009 | 19 October 2017 | Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy | A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy | IgA Nephropathy | Drug: Intravenous Rituximab;Drug: ACE/ARB;Dietary Supplement: Omega-3 Fatty Acid Fish Oil Supplement | Mayo Clinic | Ohio State University;Stanford University;University of North Carolina, Chapel Hill;Columbia University;Genentech, Inc.;Biogen | Not recruiting | 18 Years | 70 Years | All | 34 | Phase 4 | United States |
| 94 | ChiCTR-TRC-09000607 | 2008-12-01 | 18 April 2017 | Observation for Efficacy of methylprednisolone and combined therapy of methylprednisolone and mycophenolate mofetil for IgA nephropathy | Efficacy Observation of methylprednisolone and combined therapy of methylprednisolone and mycophenolate mofetil for IgA nephropathy | IgA nephropathy | A:Methylprednisolone 0.4mg/kg * 8 weeks, reduction to 5mg / d to maintain, MMF 0.75 bid * 6 months after the reduction (weight <50kg, MMF0.5 bid);B:ethylprednisolone 0.4mg/kg*8 weeks, reduction to 5mg / d to maintain; | Zhongshan Hospital of Fudan University | Not Recruiting | 18 | 70 | Both | A:40;B:40; | Post-market | China | |
| 95 | NCT00554502 | February 2008 | 6 October 2015 | Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy | Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy | IgA Nephropathy | Drug: supportive therapy with: ACE-inhibitor / ARB / Statin;Drug: supportive and immunosuppressive therapy | RWTH Aachen University | Not recruiting | 18 Years | 70 Years | Both | 148 | Phase 3 | Germany | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 96 | EUCTR2007-000871-41-DE | 24/01/2008 | 10 July 2015 | Supportive versus Immunosuppressive Therapy for the treatment Of Progressive IgA Nephropathy - STOP IgAN | Supportive versus Immunosuppressive Therapy for the treatment Of Progressive IgA Nephropathy - STOP IgAN | IgA nephropathy (IgAN) as the most common type of glomerulonephritis. MedDRA version: 16.1 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders | Product Name: Azathioprine Pharmaceutical Form: Tablet INN or Proposed INN: AZATHIOPRINE CAS Number: 446-86-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Product Name: Cyclophosphamid Pharmaceutical Form: Tablet INN or Proposed INN: CYCLOPHOSPHAMIDE CAS Number: 50180 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Product Name: Prednisolon Pharmaceutical Form: Tablet INN or Proposed INN: PREDNISOLONE CAS Number: 50248 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 50- Product Name: Methylprednisolon Pharmaceutical Form: Solution for infusion INN or Proposed INN: METHYLPREDNISOLONE CAS Number: 83432 Concentration unit: g gram(s) Concentration type: equal Concentration number: 1- Product Name: supportive therapy Pharmaceutical Form: Tablet | RWTH Aachen | Not Recruiting | Female: yes Male: yes | 148 | Germany | ||||
| 97 | NCT00599963 | January 2008 | 10 August 2015 | Paricalcitol for the Treatment of Immunoglobulin A Nephropathy | Paricalcitol for the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over Study | IgA Nephropathy | Drug: paricalcitol | Chinese University of Hong Kong | Not recruiting | 18 Years | 65 Years | Both | 0 | Phase 3 | Hong Kong;China | |
| 98 | NCT00549692 | November 2007 | 19 February 2015 | Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy | Minimization, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of IgA Nephropathy | IgA Nephropathy | Drug: Omega-3 fatty acid ethylester90 | Kuhnil Pharmaceutical Co., Ltd. | Pronova BioPharma ASA | Not recruiting | 18 Years | N/A | Both | 152 | Phase 3 | Korea, Republic of |
| 99 | NCT00657059 | September 2007 | 17 September 2018 | Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN) | A Prospective, Multicenter, Randomized Controlled Trial of Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN) | IgA Nephropathy | Drug: irbesartan;Drug: methylprednisolone (MP) or prednisone (pred);Drug: mycophenolate mofetil (MMF) | Sun Yat-sen University | Not recruiting | 14 Years | 60 Years | All | 151 | Phase 3 | China | |
| 100 | NCT00793585 | July 2007 | 19 October 2017 | A Controlled Study of Uric Acid on the Progression of IgA Nephropathy | A Prospective, Randomized Controlled Study of Uric Acid on the Progression of IgA Nephropathy | IgA Nephropathy | Drug: allopurinol;Other: continue their usual therapy | Sun Yat-sen University | Not recruiting | 18 Years | 70 Years | All | 40 | N/A | China | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 101 | NCT00426348 | May 2007 | 19 February 2015 | A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy | A Prospective Randomized, Controlled, Double Blinded Trial of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy | Glomerulonephritis;IGA Nephropathy | Drug: Valsartan;Drug: Probucol;Drug: Placebo | Guangdong General Hospital | Not recruiting | 18 Years | 60 Years | Both | 75 | Phase 4 | China | |
| 102 | JPRN-UMIN000002474 | 2007/01/01 | 2 April 2019 | Preventive effect of vit K, vit D and, risedronate on 3-dimensional trabecular microstructure in patients with IgA nephropathy on glucocorticoid treatment | Glucocorticoid induced osteoporosis in patients with IgA nephropathy | Menatetrenone 45mg/day for 6 months Calcitriol 0.5 microgram/day for 6 months Risedronate 17.5mg/week for 6 months | Osaka University Hospital Department of nephrology | Not Recruiting | 18years-old | Not applicable | Male and Female | 30 | Not applicable | Japan | ||
| 103 | JPRN-UMIN000000593 | 2006/11/01 | 2 April 2019 | Randomized controlled trial of mizoribine for progressive IgA nephropathy | IgA nephropathy with moderate to severe histological alterations | Methylprednisolone pulse therapy followed by oral prednisolone administration Methylprednisolone pulse therapy followed by oral prednisolone and mizoribine administration | West Japan Study Group for Therapy of IgA Nephropathy | Not Recruiting | 15years-old | 60years-old | Male and Female | 120 | Not selected | Japan | ||
| 104 | NCT00319761 | May 2006 | 19 February 2015 | Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy | The Safety and Short-Term Efficacy of Calcitriol in the Treatment of Immunoglobulin A Nephropathy | IGA Nephropathy | Drug: Calcitriol | Chinese University of Hong Kong | Not recruiting | 18 Years | 65 Years | Both | 10 | Phase 4 | Hong Kong | |
| 105 | ChiCTR-TRC-06000004 | 2006-01-01 | 18 April 2017 | ACEi/ARB alone versus ACEi/ARB plus Steroids in the treatment of primary IgA nephropathy, a randomized multicenter controlled trial | ACEi/ARB alone versus ACEi/ARB plus Steroids in the treatment of primary IgA nephropathy, a randomized multicenter controlled trial | primary IgA nephropathy | group 1:treated with ACEI/ARB( ARB therapy is subjected to patients with cough after use of ACEI) Inhibace (cilazapril): start at 1.25mg/day, increase the dose by 1.25mg/day/week to 2.5-5mg/day Cozaar (losartan): 25~50mg/day, increased to 50~100mg/day Last for one year;group 2:Oral prednisone for 6 mos 0.8mg/kg/day x 8 wks Tapered 0.2mg/kg/day/mo in combination with ACEI/ARB; | The First Hospital, Peking University | Not Recruiting | 16 | 65 | Both | group 1:78;group 2:78; | Post-market | China | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 106 | NCT00378443 | January 2006 | 19 February 2015 | ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCT | Glomerulonephritis, IGA | Drug: prednisone + Inhibace/Cozaar;Drug: Inhibace/Cozaar | Peking University | Not recruiting | 16 Years | 65 Years | Both | N/A | ||||
| 107 | EUCTR2005-002610-37-ES | 05/12/2005 | 19 March 2012 | PILOT TRIAL OF TREATMENT OF POOR-PROGNOSIS IgA NEPHROPATHY WITH LOW EXPOSURE TO SIROLIMUS. Ensayo clínico piloto de tratamiento de la nefropatía IgA con factores de mal pronóstico con dosis bajas de sirolimus | PILOT TRIAL OF TREATMENT OF POOR-PROGNOSIS IgA NEPHROPATHY WITH LOW EXPOSURE TO SIROLIMUS. Ensayo clínico piloto de tratamiento de la nefropatía IgA con factores de mal pronóstico con dosis bajas de sirolimus | To test in a pilot trial the efficacy and tolerance of sirolimus oral (at low doses) in patient to treat poor-prognosis IgA Nephropathy. | Trade Name: RAPAMUNE Product Name: SIROLIMUS Pharmaceutical Form: Oral solution INN or Proposed INN: Sirolimus Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1- Trade Name: RAPAMUNE Product Name: SIROLIMUS Pharmaceutical Form: Tablet INN or Proposed INN: Sirolimus Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Trade Name: RAPAMUNE Product Name: SIROLIMUS Pharmaceutical Form: Tablet INN or Proposed INN: Sirolimus Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- | NEPHROLOGY DEPARTMENT (HOSPITAL UNIVERSITARY OF BELLVITGE) | Authorised | Female: yes Male: yes | 30 | Spain | ||||
| 108 | EUCTR2005-003885-40-IT | 18/10/2005 | 24 July 2012 | ACE-inhibitors and Angiotensin two receptor antagonists in IgA nephropathy with mild proteinuria - | The primary aim of the study consists in testing the hypothesis that blockade of the RAS may decrease the risk of developing adverse effects in patients with benign IgAN.Such blockade would first achieved with unique pharmacological class then shifting to the association of the two classes as soon as ineffective blockade is documented MedDRA version: 9.1 Level: SOC Classification code 10038359 Term: Renal and urinary disorders | Product Name: Ramipril Pharmaceutical Form: Tablet INN or Proposed INN: Ramipril CAS Number: 87333-19-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Product Name: Irbesartan Pharmaceutical Form: Tablet INN or Proposed INN: Irbesartan CAS Number: 138402-11-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- | AZIENDA OSPEDALIERA PROVINCIALE DI LECCO | Not Recruiting | Female: yes Male: yes | Italy | ||||||
| 109 | NCT00767221 | October 2005 | 19 February 2015 | Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study | Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study | IGA Nephropathy | Drug: Budesonide | Pharmalink AB | Archimedes Development Ltd | Not recruiting | 18 Years | N/A | Both | 20 | Phase 2 | Sweden |
| 110 | JPRN-C000000006 | 2005/01/01 | 2 April 2019 | Lisinopril only and a combination of lisinopril and losartan for IgA nephropathy with focal mesangial proliferation in children: A randomized controlled trial of efficacy and safety | IgA nephropathy in children | Lisinopril for 2 years Lisinopril+losartan for 2 years | Japanese Study group of Kidney Disease in Children | Not Recruiting | 2years-old | 18years-old | Male and Female | 110 | Not selected | Japan | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 111 | JPRN-C000000341 | 2004/04/01 | 2 April 2019 | Randomised controlled trial of multiple drugs combined therapy for diffuse IgA nephropathy | Refractory IgA nephropathy | Prednisolone and anti-thrombocyte and angiotensin II receptor blocker or angiotensin converting enzyme inhibitor inhibitor mizoribine and Prednisolone and anti thrombocyte and angiotensin II receptor blocker or angiotensin-converting enzyme | Japanese Study Group of Multiple drug therapy for IgAN | Not Recruiting | 16years-old | 75years-old | Male and Female | 60 | Not selected | Japan | ||
| 112 | ChiCTR-TRC-09000630 | 2004-01-01 | 18 April 2017 | Treatment of Early Immunoglobulin A Nephropathy by the Angiotensin Converting Enzyme Inhibitor Ramipril - A Randomized Controlled Trial | Treatment of Early Immunoglobulin A Nephropathy by the Angiotensin Converting Enzyme Inhibitor Ramipril - A Randomized Controlled Trial | IgA nephropathy | Two groups:ramipril 5 years versus no treatment; | The Chinese University of Hong Kong | Recruiting | 0 | 0 | Male | Two groups:60; | Other | China | |
| 113 | JPRN-C000000380 | 2003/04/01 | 2 April 2019 | The renoprotective effects of ARB in patients with IgA nephropathy : multicenter,radomized trial | IgA nephropathy | ARB valsartan ACE-I enalapril | ARB therapeutic society of IgA nephropathy | Not Recruiting | 16years-old | 75years-old | Male and Female | 400 | Phase 4 | Japan | ||
| 114 | NCT00301600 | January 2003 | 19 February 2015 | Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA Nephropathy | Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA Nephropathy | IGA Nephropathy | Drug: Mycophenolate mofetil | Nanjing University School of Medicine | Not recruiting | 12 Years | 65 Years | Both | 40 | N/A | China | |
| 115 | NCT01225445 | April 2002 | 19 February 2015 | Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial | Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial | Biopsy-confirmed IgA Nephropathy;Proteinuria Less Than 0.5 g Per Day;Normal Blood Pressure;Serum Creatinine Below 120 Umol/l | Drug: Ramipril | Chinese University of Hong Kong | Not recruiting | 18 Years | 25 Years | Both | 60 | Phase 3 | Hong Kong | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 116 | NCT00863252 | March 2002 | 19 February 2015 | Mycophenolate Mofetil for IgA Nephropathy | A Prospective, Randomized, Open Label, Case-Controlled Study on the Efficacy of Mycophenolate Mofetil for IgA Nephropathy Patients With Heavy Proteinuria Despite Angiotensin Blockade | IGA Nephropathy | Drug: mycophenolate mofetil;Drug: angiotensin blockade | The University of Hong Kong | United Christian Hospital;Queen Mary Hospital, Hong Kong | Not recruiting | 18 Years | 70 Years | Both | 40 | Phase 4 | China |
| 117 | NCT00318474 | January 2002 | 19 October 2017 | Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy | A Randomized Controlled Trial of Mycophenolate Mofetil in Patients With IgA Nephropathy | IgA Nephropathy | Drug: Mycophenolate Mofetil (MMF);Drug: MMF Placebo;Drug: ACEi;Drug: FOS | St. Joseph's Hospital and Medical Center, Phoenix | Not recruiting | 7 Years | 70 Years | All | 184 | Phase 3 | United States | |
| 118 | JPRN-C000000363 | 2001/08/01 | 2 April 2019 | A combination of prednisolone and mizoribine and a combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial prolideration in children:A randomized controlled trial of efficacy and safety | IgA nephropathy in children | prednisolone+mizoribine for 2 years prednisolone+mizoribine+warfarin+dipyridamole for 2 years | The Japanese Pediatric IgA Nephropathy of Treatment Study Group | Not Recruiting | 2years-old | 18years-old | Male and Female | 80 | Not selected | Japan | ||
| 119 | NCT00006137 | May 2000 | 19 February 2015 | Pilot Study of Enalapril and Renal Function in Patients With IgA Nephropathy | IGA Glomerulonephritis | Drug: enalapril | National Center for Research Resources (NCRR) | Stanford University | Not recruiting | 13 Years | 60 Years | Both | 43 | N/A | ||
| 120 | NCT01392833 | December 1999 | 19 February 2015 | Steroids and Azathioprine in Advanced IgAN | Steroids and Azathioprine in Early and Advanced IgA Nephropathy: Amendments to a Prospective Randomised Multicenter Trial | IgA Nephropathy;Chronic Kidney Disease | Drug: methylprednisolone;Drug: azathioprine;Drug: prednisone | A. Manzoni Hospital | Not recruiting | 16 Years | 70 Years | Both | 46 | Phase 3 | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 121 | JPRN-C000000373 | 1998/08/01 | 2 April 2019 | Lisinopril for IgA nephropathy with focal mesangial proliferation in children | IgA nephropathy in children | Lisinopril for 2 years | The Japanese Pediatric IgA Nephropathy of Treatment Study Group | Not Recruiting | 2years-old | 18years-old | Male and Female | 50 | Not selected | Japan | ||
| 122 | JPRN-C000000374 | 1998/08/01 | 2 April 2019 | A combination of prednisolone, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial proliferation in children. | IgA nephropathy in children | prednisolone+warfarin+dipyridamole for 2 years | The Japanese Pediatric IgA Nephropathy of Treatment Study Group | Not Recruiting | 2years-old | 18years-old | Male and Female | 20 | Not selected | Japan | ||
| 123 | JPRN-C000000375 | 1998/08/01 | 2 April 2019 | A combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with nephrotic syndrome and diffuse mesangial proliferation in children. | IgA nephropathy in children | prednisolone+mizoribine+warfarin+dipyridamole for 2 years | The Japanese Pediatric IgA Nephropathy of Treatment Study Group | Not Recruiting | 2years-old | 18years-old | Male and Female | 20 | Not selected | Japan | ||
| 124 | NCT00755859 | May 1998 | 19 February 2015 | Steroids and Azathioprine Versus Steroids Alone in IgAN | Corticosteroids and Azathioprine Versus Corticosteroids Alone in IgA Nephropathy: a Randomized Controlled Trial. | IGA Nephropathy | Drug: steroids plus azathioprine;Drug: steroids | A. Manzoni Hospital | Not recruiting | 16 Years | 70 Years | Both | 206 | Phase 4 | Italy;Switzerland | |
| 125 | NCT00367562 | January 1996 | 19 February 2015 | Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy | Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy | IGA Nephropathy | Drug: ENALAPRIL VALSARTAN METHYLPREDNISONE | Hospital Britanico | Not recruiting | 21 Years | 70 Years | Both | 20 | Phase 4 | Argentina |